An enhanced growth inhibition is observedwhen neuroblastoma cells are treated with a PPARγligand and a HDAC inhibitor, thus suggesting that a combination therapy totreat neuroblastoma might prove more effective than using either agent alone [80].These findings suggest that a combination therapy using PPARγagonists and HDAC inhibitors might therefore be potentially effective for thetreatment of some types of human malignancies. Here, HDAC9 is linked to neuroblastoma.